

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-3. (cancelled).

4. (original) A compound that is

3-(3-bromobenzyl)-11-methyl-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

3,11-bis(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

11-acetyl-3-(3-bromobenzyl)-1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (currently amended) A pharmaceutical composition which is comprised of a compound in accordance with Claim 4 and a pharmaceutically acceptable carrier.

6-8. (cancelled).

9. (currently amended) A method of treating or preventing a PK-related disorder, wherein the PK-related disorder is an IGF-1R-related disorder selected from: cancer, diabetes, a hyperproliferation disorder, and acromegaly in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 4.

10. (cancelled).

11. (currently amended) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 4.

12. (currently amended) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim + 21.

13. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim + 21 in combination with a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) an angiogenesis inhibitor.

14. (original) The method of Claim 13, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

15. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim + 21 in combination with radiation therapy.

16. (original) The method of Claim 15 wherein radiation therapy is also administered.


17. (currently amended) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim + 21 and paclitaxel or trastuzumab.

18. (currently amended) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim + 21 and a GPIIb/IIIa antagonist.

19. (original) The method of Claim 18 wherein the GPIb/IIIa antagonist is tirofiban.

20. (currently amended) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim + 21 in combination with a COX-2 inhibitor.

21. (new) A compound of Formula I



wherein:

R<sup>1</sup> is independently selected from

- 1) H,
- 2) halo,
- 3) OR<sup>4</sup>,
- 4) NO<sub>2</sub>,
- 5) -S(O)<sub>m</sub>R<sup>4</sup>,
- 6) CN
- 7) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 8) unsubstituted or substituted aryl,
- 9) unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkenyl,
- 10) unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 11) unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub> alkynyl,
- 12) unsubstituted or substituted heterocycle,
- 13) -C(O)R<sup>4</sup>,
- 14) C(O)OR<sup>4</sup>,
- 15) C(O)N(R<sup>4</sup>)<sub>2</sub>,

- 16)  $S(O)mN(R^4)_2$ , and
- 17)  $N(R^4)_2$ ;

$R^2$  is selected from

- 1) H,
- 2)  $C_1-C_6$  alkyl, and
- 3)  $(C=O)C_1-C_6$  alkyl,

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

$R^3$  is

- 1)  $C_1-C_6$  alkyl

wherein said alkyl is optionally substituted with phenyl wherein said phenyl is optionally substituted with halo;

$R^4$  is independently selected from

- 1) H,
- 2) unsubstituted or substituted  $C_1-C_{10}$  alkyl,
- 3) unsubstituted or substituted  $C_3-C_{10}$  cycloalkyl,
- 4) unsubstituted or substituted aryl,
- 5) unsubstituted or substituted heterocycle, and
- 6)  $CF_3$ ;

$m$  is independently 0, 1 or 2;

$s$  is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.